Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2022-08-02 Sale | 2022-08-02 5:40 pm | Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO | 2,000 | $11.97 | $23,940 | 540,257 (Direct) | View |
| 2022-07-05 Sale | 2022-07-06 4:16 pm | Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO | 2,000 | $11.44 | $22,880 | 542,257 (Direct) | View |
| 2022-06-21 Sale | 2022-06-22 4:47 pm | Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO | 2,000 | $11.18 | $22,360 | 544,257 (Direct) | View |
| 2022-05-19 Sale | 2022-05-19 5:40 pm | Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO | 11,500 | $7.3993 | $85,092 | 546,257 (Direct) | View |
| 2022-03-15 Sale | 2022-03-17 5:59 pm | Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO | 5,169 | $7.709 | $39,848 | 320,119 (Direct) | View |
| 2021-10-01 Sale | 2021-10-04 5:55 pm | Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO | 11,507 | $24.35 | $280,185 | 323,928 (Direct) | View |
| 2021-03-15 Sale | 2021-03-17 5:01 pm | Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO | 2,798 | $38.05 | $106,471 | 110,035 (Direct) | View |
| 2020-10-07 Sale | 2020-10-08 5:10 pm | Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO | 16,538 | $39.4 | $651,515 | 111,677 (Direct) | View |
| 2020-10-01 Sale | 2020-10-02 4:40 pm | Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO | 9,752 | $36.37 | $354,662 | 128,215 (Direct) | View |
| 2019-08-06 Sale | 2019-08-07 9:00 pm | Adaptimmune Therapeutics PLC | ADAP | Amado Rafael President, R&D | 11,043 | $2.06 | $22,749 | 17,237 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-04-03 Exercise | 2024-04-05 5:47 pm | N/A N/A | Zai Lab Ltd | ZLAB | Amado Rafael See Remarks | 5,391 | $0 | 39,705 (Direct) | View |
| 2024-04-03 Exercise | 2024-04-05 5:47 pm | N/A N/A | Zai Lab Ltd | ZLAB | Amado Rafael See Remarks | 5,391 | $15.9 | 39,705 (Direct) | View |
| 2024-04-01 Option Award | 2024-04-03 9:43 pm | N/A 2034-04-01 | Zai Lab Ltd | ZLAB | Amado Rafael See Remarks | 198,233 | $0 | 198,233 (Direct) | View |
| 2023-12-29 Exercise | 2024-01-03 7:26 pm | N/A N/A | Zai Lab Ltd | ZLAB | Amado Rafael See Remarks | 42,000 | $0 | 106,637 (Direct) | View |
| 2023-05-01 Option Award | 2023-05-02 4:14 pm | N/A 2033-04-30 | Poseida Therapeutics Inc. | PSTX | Amado Rafael Director | 94,500 | $0 | 94,500 (Direct) | View |
| 2023-04-03 Option Award | 2023-04-05 4:05 pm | N/A 2033-04-03 | Zai Lab Ltd | ZLAB | Amado Rafael See Remarks | 134,781 | $0 | 134,781 (Direct) | View |
| 2022-12-30 Option Award | 2023-01-03 4:10 pm | N/A 2032-12-30 | Zai Lab Ltd | ZLAB | Amado Rafael See Remarks | 309,700 | $0 | 309,700 (Direct) | View |
| 2022-10-07 Option Award | 2022-10-11 4:35 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D | 19,120 | $0 | 541,946 (Direct) | View |
| 2022-10-07 Tax Withholding | 2022-10-11 4:35 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D | 8,464 | $11.83 | 541,946 (Direct) | View |
| 2022-10-03 Tax Withholding | 2022-10-05 4:02 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D | 8,968 | $11.06 | 531,290 (Direct) | View |
| 2022-03-23 Option Award | 2022-03-25 5:52 pm | N/A 2032-03-23 | Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO | 605,947 | $0 | 926,066 (Direct) | View |
| 2021-05-18 Option Award | 2021-05-20 5:22 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO | 200,534 | $0 | 335,435 (Direct) | View |
| 2021-03-26 Option Award | 2021-03-30 4:47 pm | N/A 2031-03-26 | Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO | 117,231 | $0 | 227,266 (Direct) | View |
| 2020-03-18 Option Award | 2020-03-20 4:37 pm | N/A 2030-03-17 | Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO | 140,400 | $0 | 245,562 (Direct) | View |
| 2019-09-03 Option Award | 2019-09-05 4:44 pm | N/A 2029-09-02 | Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO | 265,792 | $0 | 265,792 (Direct) | View |